R eview of the evidence on hypovitaminosis D as a risk factor for metabolic syndrome and its sequelae, T2DM and CVD, suggests long-term vitamin D repletion could reduce these risks. There is mechanistic evidence for protective effects for MetS and the balance of evidence, (cross-sectional and prospective), supports this postulate. Much of the data so far available from randomized controlled trials is weakened by inadequate power, low vitamin D dosages, starting supplementation too late in life or after MetS disorders have developed or, most importantly, by non-inclusion of many recognizable confounders. On balance, therefore, maintenance of US 2010 recommended intakes for bone protection has the potential to prove protective for MetS. Supplementation has been shown to increase survival in patients with cardiac disorders; whether higher doses would provide useful protection for apparently healthy people in the general population awaits the outcomes of ongoing randomized-controlled trials that, it is hoped, will prove or disprove causality for hypovitaminosis D in MetS and its long-term ill-effects.
Metabolic Syndrome
Obesity is associated with increased risks for dying of heart disease, stroke or heart failure, suddenly or after prolonged periods of disability. Fatty arterial deposits (plaque), arterial hardening, plaque rupture and subsequent thrombosis with vessel occlusion are recognized as precipitating cardiovascular disease, especially with hypertension. These problems are one of the most common causes of death and seen increasingly in younger people. Efforts to identify avoidable causes of vascular disease have intensified. Risk markers for CVD, additional to obesity, include hyperlipidemia (raised blood cholesterol, LDL-C and TAGs) but lowered HDL-C, hyperglycemia, type 2 diabetes (T2DM) and hypertension, the easily measured variables that have become grouped together for identification of T2DM and CVD risks. The terms "syndrome X" (Reaven syndrome), or "metabolic syndrome," as more commonly used, mark increased CVD risk by using "cut-offs" defining increased risk identified from prospective epidemiological data. These criteria vary between population groups (see Table 1 ) and do not include risk factors like increased insulin resistance or non-alcoholic fatty liver disease, or well established risk factors like lack of exercise or smoking. Unidentified risk factors for MetS could also emerge, confounding current risk assessments. It has been suggested from evidence accumulating over the past 40 y that maintaining vitamin D repletion might prove protective against MetS and its sequelae, T2DM and cardiovascular disease; 2,3 this commentary, therefore, aims to consider currently available evidence for hypovitaminosis D as a potentially avoidable risk factor for metabolic syndrome (MetS) and its sequelae.
Vitamin D. Summer sunshine and cod-liver oil have been known for many generations to prevent, and cure, childhood rickets and vitamin D was identified~100 y ago as the active agent. Unicellular organisms synthesize vitamin D, thought to be protective pre-historically against intense ultravoilet-B irradiation (UVB), which passes up the food chain, concentrating in fish-oil and fish-liver oils and also synthesized as cholecalciferol
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Factors causing vitamin D insufficiency. As mankind migrated from Africa toward the poles it met shorter days and sunlight which penetrates the atmosphere more obliquely, reducing available UVB. This was partially compensated for by reductions in skin pigmentation. 6 Modern life styles, however, reduce UVB exposure further, due to clothing (especially veiling), working, traveling and exercising indoors (since glass blocks out UVB). Air pollution blocks UVB radiation and we increasingly avoid sunshine and use sunscreens to avoid skin aging and skin cancers. People live longer and skin synthesis and gut absorption of vitamin D fall with age. Modern unfortified diets provide little vitamin D other than in wild (but not farmed) oily sea or fresh water fish, fish-liver oils and egg yolk. Increasing obesity reduces serum 25(OH)D, probably by sequestrating vitamin D in adipose cell fat. 7 Vitamin D need only be stored at the same concentrations in fat in obesity as in nonobese people for total vitamin D storage to be increased by obesity. 8 This stored vitamin D can be released during weight loss, e.g., after gastric banding, when insulin resistance and serum PTH fall. (PTH) can increase insulin resistance. 9, 10 Malabsoptive weight loss, which reduces serum 25(OH)D, also reduces insulin resistance. Thus, weight and weight changes are common confounders of investigations in this area. Some countries fortify foods, e.g., milk and orange juice in the USA and margarine in the UK and often some breakfast cereals. Inadequate vitamin D repletion is a continuing, sizeable and increasingly obvious problem world-wide, in sunny as well as Northern climes, and at all ages. 10, 11 More countries are introducing food fortification with vitamin D, using D 3, since D 3 may be more effective than D 2 , even though both cure rickets. 4, 12 Genetic influences on vitamin D "status." Three polymorphisms in vitamin D axis genes contribute independently to determination of serum 25 16, 17 Factors increasing metabolic syndrome disorder risks. Recognized life-style and environmental factors increasing risks of MetS and its sequelae, CVD and T2DM, include lack of exercise, increasing age, obesity, cigarette smoking, excess alcohol intake and inappropriate diet; programmes of regular exercise with weight loss can reduce T2DM risk by up to 58%. 18, 19 Further reductions are seen with other measures for reducing insulin resistance, or improving β cell function, e.g., medication with metformin, renin-angiotensin system blockers, incretin mimics or bariatric surgery. 20 Since correcting severe hypovitaminosis D can produce similar benefits, experimentally, and in some subjects with early defects in glucose homeostasis, 2 this commentary aims to consider the case for definitive investigation of long-term vitamin D repletion for reductions of MetS risks, since this measure could prove cost-effective at the population level.
Vitamin D insufficiency and metabolic syndrome abnormalities. Since many of the factors leading to increased MetS risk 21 Higher than recommended intakes of vitamin A are associated with health risks and can be above recommendations in some communities, especially in the West. 22, 23 Osteoporosis is more severe and fragility fracture rates increased in women with higher retinol intakes. Thus, retinol intake is an unmeasured confounder in all studies of vitamin D and MetS to date and should be assessed in all future studies, including RCTs.
Vitamin D status and metabolic syndrome. Available evidence includes reports of associations, mechanisms and effects of supplemental vitamin D in relation to classical metabolic syndrome (MetS), its components, related risk factors (including increased insulin resistance and nonalcoholic fatty liver disease) and its sequelae. Over 60 reports, identified using keywords "syndrome X"/"metabolic syndrome" and "vitamin D," updating evidence reviewed by the author in 1998 2 are now discussed. These include crosssectional, prospective, supplementational and RCT studies, mostly examining population-based cohorts, subjects with early MetS abnormalities or T2DM.
Evidence . European cohort data on 3,369 men (mean age 60 ± 11 y) gave similar findings, independent of PTH, but were attenuated by adjustment for insulin resistance, suggesting this was the factor accounting for the association of vitamin D status with MetS. 31 34 and in British south Asians. 35 In Scandinavia, higher serum 25(OH)D was also associated with less abnormal lipid profiles crosssectionally, and lower serum TAGs prospectively over 14 y. 36 Review of data for lipid profiles and vitamin D status from 22 cross-sectional studies (each of . 500 subjects) and 10 placebo-controlled trials of supplementation (each of . 50 subjects) showed 25(OH)D related directly to HDL-C, and inversely with TAGs, but results from trials of supplementation were inconsistent (none was designed to study lipids or had sufficient power); though one RCT showed 16% reductions in TAGs there were concomitant LDL-C increases. 37 In 1,330 Koreans, aged . 40 y, low 25(OH)D marked increased MetS risk after adjustment for PTH and calcium cross-sectionally; it also predicted increased incident hypertension over the next 4 y. 39 In sunny California, 25(OH)D values were , 20 ng/ml (50 nmol/l) in 30% of subjects with MetS and 8% of controls, p , 0.025) and correlated inversely with fasting glucose and HOMA-IR (r = 0-0.29 and -0.34 respectively, p , 0.04) after adjustment. 40 Low 25(OH)D is common in polycystic ovary disease (PCOS) and was associated with reduced insulin responses to glucose challenge in 47 young Australian women, independent of their BMI; in 206 Austrian women with PCOS, low 25(OH)D was associated with increased insulin resistance, independent of the similar effects of increased BMI. 41, 42 In Italian children poor vitamin D status was associated with MetS, its components and insulin resistance. 43 Irish people aged
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20-40 y showed inverse associations of vitamin D status with MetS abnormalities and other CVD risk factors, as in older people. 44 Iranians with T2DM show similar associations. 45 Obesity is increasingly common, even in children and adolescents and 25(OH)D is associated inversely with obesity. 7 Thus findings independent of obesity are of especial significance, since MetS risk increases with increasing obesity. 46 Better vitamin D status, however, is associated with lesser degrees of abnormality in lipid profiles, which can be independent of obesity. 47 Non-alcoholic fatty liver disease (NAFLD) is common in MetS and in obesity and is currently considered part of the MetS. 21 73 These data were later re-analyzed, with additional Finnish data, totalling 8267 healthy adults at baseline with 226 incident cases of T2DM over 10 y follow up. Baseline overweight was the strongest predictor of T2DM and, together with reduced exercise, excessive alcohol intake, smoking and low serum 25(OH)D, accounted for 82% of the T2DM risk. 74 Framingham offspring study data showed increased fasting glucose was predicted by lower baseline 25(OH)D after 7 y in 2571 people initially free of diabetes (mean age 54 y), after adjustment for other related factors; similarly, low 25(OH)D values predicted increased incident T2DM and cardiovascular events in a study of over 40,000 Americans. 59, 60 Five-year follow up from 1999-2000 of 6,537 subjects showed those developing T2DM (n = 199) had lower baseline 25(OH)D than others (58 nmol/l vs. 65 nmol/l, p , 0.001); each 25 nmol/l increase in 25(OH)D at baseline predicted a 24% reduction in 5y T2DM incidence [RR = 0.76 (95% CI, 0.6300-0.92)] after adjustment for all recognized risk factors including non-glycaemic MetS variables and T2DM family history. by adjustment for obesity. 76 80 Larger doses (100,000 IU twice, 2 weeks apart) did not change glucose or insulin in 35 vitamin D insufficient adults in Australia in those with or without glucose intolerance at baseline. 81 Baseline 25(OH)D in the PROMISE study predicted better β cell function and lower glycaemia at GTT and related inversely to insulin resistance at 3-y follow up in 489 subjects (50 ± 10 y and "at-risk" of diabetes), after adjustment for relevant risk factors, baseline insulin resistance, changes in physical activity and use of vitamin D supplements, but additional adjustment for baseline and final BMI destroyed the association with HOMA-IR. 82 59 obese Saudis examined before and after one year of vitamin D rich diet and encouragement to sunbathe (avoiding 11 a.m.-3 p.m.) showed reduction in MetS prevalence (13% from 25.2%), without weight loss, largely due to reductions in LDL-C, TAGs and hypertension, despite only increasing mean 25(OH)D from 18.75 to 33.25 nmol/l. 83 Calcitriol treatment in a 12-week RCT in 70 people aged 30-75 y with T2DM prevented increases in fasting glucose and increased insulin secretion vs. controls but without improved control. 84 Inflammatory markers of CVD risk were reduced by 1 y low-dose supplementation in a small but adequately powered RCT in~50 South Asians at-risk of diabetes; CRP by 23% and plasma MMP9 by 67%. 85 92 subjects at high risk of T2DM (mean age 57 y) in a RCT of 2000 IU vitamin D 3 /day showed improved β cell function and reduced HbA1c increases vs. controls (supplemental calcium had no effects). 86 28 Indians with moderately controlled T2DM showed no changes in glycaemia, insulin secretion or resistance after 4 weeks vitamin D. 87 An RCT of supplementation of people with T2DM and vitamin D deficiency, using fortified yoghurt drinks providing 500 IU of vitamin D 3 per day, reduced circulating markers of inflammation including TNFa, IL-6 and hsCRP but increased circulating anti-inflammatory factors such as IL-10 and the significance of these improvements was not abolished by adjustment for changes in insulin resistance. 89 Furthermore reductions in circulating markers of inflammation were seen after myocardial infarction, better vitamin D repletion was associated with improved survival. 90 Reduction in mortality with supplementation has been shown [OR for death 0.39 (95% CI, 0.277-0.534, p , 0.0001)] in patients with cardiac disorders. 91 In patients with cardiovascular disease those with heart failure (n = 3,069) were more deficient than those without (n = 46,825), unsurprising in a group with limited activity, but deficiency was associated with increased mortality in this cohort within 2 y in both those with and those without heart failure [HR = 93 Meta-analysis of trial data to 2011 showed no reductions in CVD 94 but further meta-analysis has shown reductions in mortality, prospectively, in . 95 There is also evidence that giving vitamin D 3 , but not D 2 or calcitriol, reduced overall mortality by 1 for every 161 people supplemented, mainly . 70 y old, over a median period of 2 y. 96 Further meta-analyses (of data from 28 studies covering 99,745 subjects) showed 43% reductions in cardiometabolic disorders, including MetS and cardiovascular problems (OR = 0.57, 95% CI, 0.48-0.68), for any CVD disorder, in those with the highest 25(OH)D. 97 Thus, the overall findings do suggest that better vitamin D repletion could be protective for MetS risk reduction. 98 Vitamin D deficiency in~70% of 10,899 American patients aged 58 ± 15 y followed prospectively for . 
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factors. 99 High risks of cardiovascular disease in renal failure are reduced by treating vitamin D insufficiency in studies giving activated vitamin D, or its analogs, as compensation for lost renal activation. However, most tissues activate vitamin D locally and unduly large doses of calcitriol or active analogs increase CVD risks in renal failure. Intact cholecalciferol may, therefore, prove safer and equally effective for mortality reduction. Results of RCTs testing this possibility are currently awaited. 100 Circulating inflammatory markers can sometimes fall with supplementation in severe deficiency, 85, 101, 102 supporting the possibility that adequate repletion may prove to be protective for CVD, though this is not a consistent finding and results of ongoing RCTs are needed to establish whether there is any causality or whether the reported associations are confounded. If the reported inverse associations of reduced mortality with higher status can be reproduced by increased intakes of vitamin D from fortified food or supplements, a halving of mortality could be expected from a doubling of 25(OH) vitamin D concentrations, 103 demonstrating the urgent need for adequate RCT data testing whether this potential benefit of supplementation can be achieved.
T2DM. Evidence for low vitamin D status as a risk factor for T2DM has accumulated steadily since calcium was first shown to be necessary for islet insulin secretion and release. 21, 104 There is also mechanistic evidence for several beneficial effects of vitamin D on insulin secretion, insulin resistance and β cell health. 12, 21 However, no substantive randomized controlled trials that adequately test causality have yet reported to the author's knowledge (Feb 2012). Review of vitamin D supplementation RCTs suggests reduced progression to T2DM in those at highrisk of T2DM, though there were few adequate studies and many potential confounders could not be assessed. 105 Prospectively, higher 25(OH)D predicted lower T2DM risks in a nested casecontrol study, (608 women who developed incident T2DM vs. 559 negative matched controls) in the Nurse's Health Study; RR for T2DM or those in the highest vs. lowest quartiles of 25(OH)D was 0.52 (95% CI, 0.33-0.83), 106 a finding consistent across all age, baseline BMI and calcium-intake strata. 300,000 IU of D 3 by single intramuscular injection after delivery in a RCT in 45 women, did reduce insulin resistance compared with controls and low serum 25(OH)D has predicted gestational diabetes risks in some studies but not all. 107 Calcium and metabolic syndrome. Increased serum calcium predicts increased CVD mortality prospectively; high-dose calcium supplementation is suspected to increase CVD risks, but not high dietary intakes. 108 High-dose calcium may also increase MetS risk since, as discussed above, IGT was more common among . 1,000 White people aged 40-65 y in those in the highest vs. lowest quintiles of total serum calcium [adjusted for age, obesity, season, PTH and 25(OH)D; HR = 1.63 (95% CI, 1.42-1.88)]. 65 Similarly, the Finnish FIN-D2D study found increasing prevalence of MetS and its components in 4,500 middle-aged people, with or without adjustment for other risk factors including serum 25(OH)D. 64 Supplementation. Vitamin D replacement in severe deficiency improves insulin secretion experimentally and in some, but not all, humans studies. 21, 109 In 109 Chinese patients over 50 y old with T2DM there were no such associations and no changes in MetS variables after vitamin D 3 at 2,000 IU/day for 3 mo. 111 In South Asian women in New Zealand with increased insulin resistance and serum 25(OH)D , 50 nmol/l, supplementation with 4,000 IU daily for 6 mo improved insulin sensitivity (without changing C-peptide responses), most marked in those achieving 25(OH)D $ 80 nmol/l. 112 Sub-therapeutic doses of vitamin D did not alter MetS variables or glycaemia in T2DM over 4/12, 113 but, in 92 high risk adults, mean age 57 y, vitamin D 3 , 2,000 IU/day, increased insulin secretion and insulin efficacy and led to smaller increases in HbA1c than in controls while added calcium had no effect. 86 Genetic factors. Possible variation in insulin secretion (in response to glucose) with VDR genotype is reported in some small early studies; 14 variations in expression and formation of VDR protein with VDR polymorphisms were found in PBMCs from 41 healthy South Asians while VDR expression was an independent predictor of insulin secretory capacity. Both insulin resistance, and vitamin D-induced reductions in insulin resistance with supplementation, varied with VDR polymorphism in 239 healthy, but insulin resistant, South Asian women in New Zealand. 114 VDR polymorphism was also associated with variation in insulin resistance and glucose tolerance in non-diabetic Caucasians in the larger Rancho-Barnardo study. 115 MetS variables (BMI, waist size, fasting glucose and HDL-C) varied with VDR polymorphism in Polish men while in 351 healthy older Polish women only HDL-C (and not obesity or glycaemia) varied with VDR polymorphism.
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Relevant mechanisms of action of vitamin D. Vitamin D promotes normal insulin secretory responses to glucose by promoting rapid non-genomic transfer of calcium into cells; essential for 2 of the 4 β-cell endopeptidases that release insulin from proinsulin, and increasing β cell insulin sensitivity. 118 Calcitriol also downregulates renal renin synthesis. 119 Insulin resistance increases with increased reninangiotensin system activation and is reduced by its suppression. 120 Calcitriol prevents, and can correct, the increased islet RAS activity seen in hyperglycaemia, experimentally, providing islet protection. 121 South Asians in Western countries have 4-fold increases in age-adjusted prevalence of MetS and T2DM compared with Caucasians and a higher prevalence's of vitamin D deficiency and insufficiency, commonly attributed to increased skin pigmentation and life-style differences. South Asians also need higher supplements than white Caucasians to achieve comparable 25(OH)D concentrations, perhaps because of reduced compliance. skin fibroblasts. 123 Many South Asians chew betel-nuts (from the Areca catechu palm), often wrapped in piper-betle vine leaves (as "quids" or "paan"). This fourth most commonly used addictive habit affects 10% of the world's population (between 6-7 million people), goes back 2,000-5,000 y and travels with migrants. 124 This habit may contribute to the problem, as follows: arecal alkaloids form carcinogenic nitrosamines in the gut and many nitrosamines are diabetogenic. Betel-feeding for 5 d in young CD1 mice induces obesity and hyperglycaemia in some fed animals and in many nonbetel-fed offspring of betel-fed but normoglycemic males. 125 Increased glycemia and waist size is also found in female betelchewers in the UK: in Taiwan, chewing betel (without tobacco) began after World War II, almost exclusively in men, and dose-duration of chewing relates dose-wise to increases in glycemia, MetS and T2DM and in transmission of MetS risk by chewing fathers to their non-chewing offspring, even by those without MetS or T2DM, [126] [127] [128] Thus, our finding of increased PBMC expression of the calcitriol-catabolic 24(OH)ase with increased betel-quid usage in South Asians may be relevant, especially as there were concomitant reductions in circulating calcitriol. 
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Inflammation and T2DM risk. Inflammation appears to increase insulin resistance and increase T2DM risks. Inflammatory cytokines, e.g., from adipose tissue, act remotely and can induce β-cell damage. Vitamin D modulates inflammation by reducing inflammatory cytokine secretion (e.g., IL-6), increasing anti-inflammatory cytokine secretion (e.g., IL-10) and enhancing T-regulatory cell formation; it also reduces cytokineinduced β-cell apoptosis. Furthermore, several variants of inflammatory cytokine genes are associated with variation in risk markers for MetS risk (e.g., fasting insulin, HDL-C and CRP). Vitamin D can reduce inflammatory disease severity. [131] [132] [133] [134] [135] [136] [137] [138] Variable findings are reported for associations of 25(OH)D with inflammatory and anti-inflammatory markers and supplementation in insufficiency or deficiency has corrected inflammatory marker abnormalities in some cohorts but not others. 139 Overall, the data suggest that ethnicity, baseline 25(OH)D, dose size, and how doses are given can all affect outcomes of supplementation for inflammatory disorders. 139 Such factors need to be standardized, or adjusted for, in future RCTs of vitamin D in inflammatory disorders, as for all other conditions, including MetS, along with other possible confounders and genetic variants of relevance discussed above.
Discussion
Vitamin D is unusual as it is a "vitamin" only because humanity lacks adequate summer sunlight exposure. This 'legendary multi-tasker' has established effects on many biological processes; 140 with mechanistic evidence relevant to disorders in all systems of the body. 16, 141 Nutritional rickets was eradicated in my homeland (UK) in my lifetime but has reappeared. Vitamin D deficiency is present in significant proportions of peoples across the globe. 11, 142, 143 In the USA, 75% of White and . 90% of other ethnic groups are vitamin D insufficient, a doubling of prevalence in the last 10 y, with adverse effects suggested for MetS, T2DM, CVD risks and for all other systems. 1 Vitamin D intakes in the UK remain inadequate at all ages, well below the 2010 recommendations of 400-800 IU/day from the North American Institute of Medicine, 144 and far short of the 1,000-2,000 IU/day suggested as necessary for adults by most vitamin D workers. [145] [146] [147] Despite increasing evidence of the importance of adequate vitamin D repletion for health, and mechanistic evidence on vitamin D's roles, weaknesses of RCT data for MetS, T2DM and CVD may make it impossible to get definitive answers on causation, even in current trials. Problems affecting requirements include: variation in requirements with 150 Omega-3 poly-unsaturated fatty acids from fish may be protective for CVD but these effects may be confounded by contained vitamin D, and those of vitamin D by fishoil intakes. 151 Reductions in T2DM and CVD risk with higher intakes of vitamin D may be confounded by all the factors discussed above. Furthermore, older people need larger doses than younger people and initiation of vitamin D repletion at an early age may be more effective than once MetS has begun to develop. Clearly, all of these factors should be examined in future studies on vitamin D and health, including RCTs, to reduce confounding.
Weaknesses of prospective studies include using baseline 25(OH)D measurements for assessing risk 3 to 11 y later (in one case, 22 y later). However, baseline 25(OH)D in a study of 2668 adults in Scandinavia predicted almost 50% of 25(OH)D measured after 1 y and 20-25% 14 y later (after adjustment for season). Thus, in the majority of prospective studies, baseline assessments only reflect overall status to a degree. 36 The reductions in predictive capacity of baseline serum 25(OH)D for later vitamin D status over the years 36 must confound such analyses and, since such confounding reduces the predictive role of baseline vitamin D status, the associations demonstrated may well be greater than the reported calculations suggest. 152 Poor 25(OH)D assay standardisation has been a problem but improving uptake of the vitamin D external quality assessment scheme (DEQAS; European vitamin D external quality assessment scheme; www.deqas.com) has reduced © 2 0 1 2 L a n d e s B i o s c i e n c e .
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inconsistencies between different methods and laboratories Increasing use of newer methods, e.g., liquid chromatography/ tandem mass spectrometry, may improve consistency once inherent technical challenges are overcome, and may allow micro-assays to be used for populationbased studies or audits (on dried blood spots or saliva) and in RCTs. 153 Genetic variation in vitamin D responsiveness may be detectable from biochemical and metabolomic profiling to supplement GWAS data or when genetic profiling is not feasible. 154 Despite useful efforts to determine dosages needed to optimise vitamin D status in individuals, we do not yet know how to allow for ethnicity, genetic variation and baseline status, 155, 156 and whether this would really reduce MetS risks. Enough is known to mandate avoidance of severe deficiency for bone health 144 which may itself reduce MetS risks. Intakes of~600-1,400 IU/day for example can achieve 25(OH)D concentrations of 55-75 nmol/l (Fig. 1) . 115, 119 If causality for vitamin D and MetS and its sequelae is disproved, such intakes would be protective for musculo-skeletal health and benefit pregnant women and their children, since better repletion in pregnancy leads to better bone health in children up to age 9y. 157, 158 Most importantly, such modest intakes should do no harm, intakes up to 4,000 IU/day on a regular basis being regarded as safe following IOM data review. 144 A serum 25(OH)D of 50-75nmol/l is a reasonable target for abolishing nutritional rickets and modestly protecting adult bone health and could be achieved by IOM recommended intakes, (without the need for screening blood tests), or by food fortification as recently introduced in Finland, this last being especially cost-effective, since everyone would benefit and costs would pass to consumers. 144 Intakes of 600 IU/ are estimated to achieve mean serum 25(OH)Ds of 54-55 nmol/l, IOM target levels known to reduce overt bone disease risks. For values of $ 50nmol/l, at the population level, intakes of 930 IU/day are needed, supporting the need for intakes higher than the recent IOM recommendations. 146, 159, 160 To achieve 25(OH)Ds of 75-85 nmol/ where notable reductions in insulin resistance have been achieved and at which other beneficial effects are seen, 27, 112, 129, 144, 149, [161] [162] [163] [164] needs intakes of 1,000-2,000 IU/day, doses already suggested to be necessary for adults by many vitamin D workers and medical advisory bodies. 4,146,162, Future prospects for reduction in metabolic syndrom risks by vitamin D repletion. Improved supplies of vitamin D should be ensured now by simple food fortification or by the use of modest supplements as recommended by the IOM for musculo-skeletal health. It is also urgent that vitamin D's potential for reducing non-bony disorders is tested in adequate RCTs. Furthermore, such RCTs should test vitamin D for a wide range of health outcomes in healthy people, including MetS and its many sequelae. They should also include all known confounding factors, in order to determine whether higher intakes than those now recommended for bone protection would be beneficial at the population level and, if so, at what dosages. If causality is confirmed in RCTs, public health measures could be introduced to achieve optimal vitamin D status for all by the provision of adequate intakes of vitamin D 3 . 
